Executive Order Amending Executive Order On Euphoriant Substances

Original Language Title: Bekendtgørelse om ændring af bekendtgørelse om euforiserende stoffer

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now

Read the untranslated law here: https://www.retsinformation.dk/Forms/R0710.aspx?id=124816

Executive order amending Executive order on euphoriant substances

§ 1

In executive order No. 749 of 1. July 2008 on euphoriant substances, as amended by Decree No. 1329 by 18. December 2008 and Decree No. 174 out of 10. March 2009, is amended as follows:

1. In paragraph 5 shall be added as paragraph 2:

' (2). The Danish Medicines Agency may, in accordance with the received the opinion of the National Board of health permit municipal, regional and private institutions, see. health law § 142, to receive and possess the narcotic agent that is included on list A as nr. 3, as part of medical treatment of persons for drug abuse. The Danish Medicines Agency may set conditions for the authorization. '

2. section 26 is replaced by the following: ' article 26. The Danish Medicines Agency oversees pharmacy company with narcotic drugs.

(2). Food agency oversees veterinary activities with euphoriant drugs.

(3). The Danish Medicines Agency supervises persons, undertakings, and laboratories of the Danish Medicines Agency has been given special permission for activities with euphoriant drugs.

(4). The Danish Medicines Agency may oversee the State's scientific, medical and technical laboratories and institutions in respect of their activities with euphoriant drugs.

(5). The Danish Medicines Agency oversees the institutions who have received it in § 5 (2) of the said permit, in the case of institutions receiving, handling and storage of, as well as accounts with the narcotic agent that is included on list A as nr. 3.

(6). The Danish Medicines Agency makes in paragraphs 3-5 supervision referred to so often, it is found necessary. The Danish Medicines Agency have unimpeded access to the premises, supplies, books and business records, relating to the said company. The person, the company's owner, laboratory or institution's leadership is required at all times to disclose any information relating to the company with narcotic products which the Danish Medicines Agency may wish.

(7). Deficiencies identified by the Danish Medicines Agency's supervision, shall be immediately remedied.

(8). The Danish Medicines Agency may lay down detailed rules concerning the mentioned in paragraph 3-5 supervision. '

§ 2

The notice shall enter into force on 14 July. May 2009.
The Ministry of health and prevention, the 11. May 2009 Jakob Axel Nielsen/Lars Petersen